Lines of investigation
- Development of analytical batteries for combined vaccines.
- Diagnosis of carrier status of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.
- Synthesis of tumor associated antigens of a polysaccharide nature.
- Obtaining monoclonal analytical and diagnostic applications.
- Obtaining outer membrane vesicles derived from bacteria.
- Formulation and adjuvants.
- Clinical and preclinical evaluation of vaccine candidates.
Attenuated vaccine against cholera (CV638)
The National Center for Scientific Research and the Finlay Institute of Vaccines are working on the development of an attenuated vaccine based on the genetically modified strain of Vibrio cholerae 638 (O1, El Tor biotype, Ogawa serotype). The administration of a single dose of this vaccine candidate has demonstrated a high colonizing capacity, as well as the induction of a high and protective vibriocidal immune response in clinical studies.
Multivalent vaccine against meningococcal disease
The objective of this project is the development of a multivalent vaccine against the meningococcal serogroups responsible for the majority of cases worldwide (A, B, C, Y, W, X), which is competitive in the current market, using conjugated polysaccharides or combinations thereof with proteins derived from the bacteria. These vaccine combinations have been highly immunogenic, mainly through the measurement of the induced bactericidal response.
Conjugated vaccine against Streptococcus pneumoniae em>
The candidate vaccine conjugated against Streptococcus pneumoniae called QUIMI-VIO®, was developed following the approach of achieving the greatest possible relationship between impact and cost-effectiveness with the objective of being used in Cuba and in other countries. The number of serotypes remained at 7, unlike the strategy of the current conjugate vaccines but with a selection of the serotypes of greater circulation: 6B, 14, 18C, 19F, 23F, 1 and 5. In addition, a high degree of cross protection for serotypes 6A and 19A. Our strategy allows a global vaccination coverage of 75% with a more attractive price in relation to other conjugated vaccines existing in the market.
Conjugated vaccine against typhoid fever
This project is based on the potential of conjugated vaccines to induce a long-lasting and effective immune response in infants, which differentiates them from polysaccharide vaccines. The evaluation in animal models of conjugates using the Vi polysaccharide of Salmonella Typhi and the tetanus and diphtheria toxoids as carrier proteins, has shown the induction of a high immune response as well as the production of B and T cells related to immunological memory.